Urine DNA Test for Urothelial Cancer in Lynch Syndrome
Urothelial Cancer Screening in Individuals With Lynch Syndrome Using a Urine Tumor DNA Panel (LS-URO Study)
Recruiting
N/A
Interventional Study
Urothelial Carcinoma
Lynch Syndrome
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 50 – 75
- Sex
- Any
- Study type
- Interventional
- Purpose
- Screening
- Participants needed
- 200 (estimated)
- Sponsor
- Tampere University Hospital · Other
Who this trial is looking for
This trial is looking for people with Lynch syndrome between the ages of 50 and 75. Participants will help test a urine test to find early signs of urothelial cancer, even if they don't have symptoms.
Are You a Good Fit for This Trial?
You may be able to join if
- I am willing and able to provide informed consent
- I have been diagnosed with Lynch syndrome
- I am between 50 and 75 years old
You may not be able to join if
- I have urothelial carcinoma currently
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
Lynch syndrome (LS) is an inherited cancer predisposition syndrome caused by pathogenic germline variants in DNA mismatch repair (MMR) genes. New cancer screening and diagnostic tools are urgently needed to identify LS-related cancers early enough for curative treatment. Urothelial cancers (comprising bladder and upper tract urothelial tumors) are the third most common cancer after colorectal and …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Willing and able to provide informed consent
* Diagnosis of Lynch syndrome
* Age 50 - 75 years at study recruitment
Exclusion Criteria:
* Concurrent urothelial carcinoma
Contacts